Malin Corporation | MLC - Cash And Equivalent


Malin Corporation reported EUR62.1M in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Eurofins Scientific SE EUR 791.2M 37.9M Dec/2025
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Lonza CHF 719M 188M Dec/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 1.02B 162.62M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026